Supernus Pharmaceuticals, Inc. (SUPN): Cash & Equivalents
$128.45M
As of 2025-12-31
$179.95M
As of 2026-06-30
+11.3%
3-year compound annual growth
-15.0%
5-year compound annual growth
+14.4%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $128.45M | +85.3% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $69.33M | -7.6% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $75.05M | -19.4% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $93.12M | -54.2% | 2023-03-09, Balance as of period end |
| 2021-12-31 | $203.43M | -29.5% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $288.64M | +59.1% | 2022-04-13, Balance as of period end |
| 2019-12-31 | $181.38M | -5.7% | 2021-03-08, Balance as of period end |
| 2018-12-31 | $192.25M | +91.7% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $100.30M | +51.1% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $66.40M | +98.2% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $33.50M | -8.0% | 2018-03-01, Balance as of period end |
| 2014-12-31 | $36.40M | +10.4% | 2017-03-16, Balance as of period end |
| 2013-12-31 | $32.98M | -18.2% | 2017-01-20, Balance as of period end |
| 2012-12-31 | $40.30M | -17.0% | 2015-03-12, Balance as of period end |
| 2011-12-31 | $48.54M | +104.5% | 2014-03-21, Balance as of period end |
| 2010-12-31 | $23.74M | n/a | 2013-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $128.45M | +85.3% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $170.18M | +12.2% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $158.54M | -42.7% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $205.40M | +106.4% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $120.50M | -5.6% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $165.60M | -9.8% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $421.00M | +142.0% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $231.25M | +227.7% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $322.93M | +2.4% |
Compare SUPN, AMPH, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗